Opioid/Benzodiazepine Polydrug Abuse: Aim 3

In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphine+alprazolam simultaneously, and placebo (laboratory pharmacology experiment). The latter will enable the investigators to assess the effects of an opioid alone, benzodiazepine alone, concurrent and simultaneous administration of opioid+benzodiazepine, relative to a placebo control.

NCT Number	NCT05006079
Lead Sponsor	Wayne State University Collaborators: Henry Ford Health System
Conditions	Opioid Abuse, Benzodiazepine Abuse, Polysubstance Abuse
Enrollment	24 participants
Start Date	2024-03-13
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2025-12-30